You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Details for New Drug Application (NDA): 214048


✉ Email this page to a colleague

« Back to Dashboard


NDA 214048 describes BETAMETHASONE DIPROPIONATE, which is a drug marketed by Chartwell Molecular, Fougera Pharms, Glenmark Pharms Inc, Padagis Israel, Sun Pharma Canada, Actavis Mid Atlantic, Aurobindo Pharma Ltd, Cosette, Perrigo New York, Pharmaderm, Teva, Zydus Pharms, Encube, Hikma, Alpharma Us Pharms, Fougera Pharms Inc, Padagis Us, Shree Hari Intl, Lupin Ltd, Tp Anda Holdings, and Zydus Lifesciences, and is included in forty-eight NDAs. It is available from twenty-four suppliers. Additional details are available on the BETAMETHASONE DIPROPIONATE profile page.

The generic ingredient in BETAMETHASONE DIPROPIONATE is betamethasone dipropionate. There are sixty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate profile page.
Summary for 214048
Tradename:BETAMETHASONE DIPROPIONATE
Applicant:Zydus Lifesciences
Ingredient:betamethasone dipropionate
Patents:0
Pharmacology for NDA: 214048
Mechanism of ActionCorticosteroid Hormone Receptor Agonists
Suppliers and Packaging for NDA: 214048
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BETAMETHASONE DIPROPIONATE betamethasone dipropionate OINTMENT;TOPICAL 214048 ANDA Zydus Lifesciences Limited 70771-1550 70771-1550-1 1 TUBE in 1 CARTON (70771-1550-1) / 15 g in 1 TUBE
BETAMETHASONE DIPROPIONATE betamethasone dipropionate OINTMENT;TOPICAL 214048 ANDA Zydus Lifesciences Limited 70771-1550 70771-1550-4 1 TUBE in 1 CARTON (70771-1550-4) / 45 g in 1 TUBE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:OINTMENT;TOPICALStrengthEQ 0.05% BASE
Approval Date:Jul 14, 2020TE:ABRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links